Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2021 - 12 - 13 save search
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
CMPS | $8.07 -2.18% -2.23% 890K
|
Health Technology
|
| O: -5.04%
H: 0.0%
C: 0.0%
comp360 treatment positive therapy depression psilocybin
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.03 -6.88% -7.39% 720K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Tonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal Cancers
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 0.44%
H: 0.0%
C: 0.0%
tnx-1700 als research therapy collaboration cancer colorectal cancer
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 160K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
phase 2 trial therapeutics immunotherapy potential therapy cancer
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.04 -9.79% -10.86% 2.1M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
allo-715 ema therapeutics positive results phase 1 positive therapy results t-cell
Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
CELU | News 4 | $3.385 5.45% 5.17% 36K
|
|
| O: -1.42%
H: 0.0%
C: 0.0%
ema genetic preclinical therapy pre-clinical
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ft516 fda granted therapeutics phase 1 positive therapy t-cell designation
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
nktr-255 ema car-t therapeutics therapy
FDA Approves XBiotech’s IND in RheumatologyLaunching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
XBIT | $8.075 -1.28% -1.3% 65K
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: 0.0%
fda therapy antibody biotech iot
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 14:00) - biospace.com/
APRE | $5.37 6.3% 6.3K
|
Health Technology
|
| O: -2.85%
H: 0.49%
C: -7.58%
tp53 ema phase 2 trial therapeutics therapy aml
IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 06:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -2.44%
H: 0.0%
C: 0.0%
car-t therapeutics presentation therapy iot
Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 02:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -2.44%
H: 0.0%
C: 0.0%
car-t presentation therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.